Signal Bureau What’s happening · what the record shows

KRAS G12c Mutated

A topic on our watch list — we track its coverage across 1 domain, including Gi Journal.

If KRAS G12c Mutated is on your watch list: what changed in the coverage, what the reporting asserts, and what the crowd is pricing.

What’s changed

Adagrasib plus cetuximab fails to outperform chemotherapy in KRAS G12C-mutated metastatic colorectal cancer - ESMO Daily Reporter · CRC Research (Google News) · 2026-07-03
KRYSTAL-10 at ESMO GI 2026: Adagrasib Plus Cetuximab vs Chemotherapy in KRAS G12C-Mutated mCRC - Oncodaily · CRC Research (Google News) · 2026-07-03

Ask the engine about KRAS G12c Mutated ＋ Track KRAS G12c Mutated for a daily read

Informational only — not financial, legal, or investment advice. Prediction-market prices are shown as a signal of what the crowd believes. Terms · Privacy · page rendered Jul 28, 8:30 AM PT